Munich, November 21, 2025 – Noselab is delighted to announce the resounding success of the first-ever Brain-Nose Symposium, held on Friday, November 21, 2025, at Maria’s Platzl Hotel. The event brought together leading scientists, clinicians, industry experts, and innovators from around the world to explore the emerging science and translational potential of the Brain-Nose Interface (BNI).

A Milestone for Neuroscience

The well-attended symposium exceeded all expectations. Participants highlighted the quality of the excellent presentations, spanning the physiology of the Brain-Nose Interface, analytical proteomics, clinical applications and opportunities, as well as a prospect of future innovations.

Networking played a major role for the event, with lively exchanges among participants during breaks. “We were especially pleased with the significant international interest. The symposium saw strong international participation, as well as attendees traveling from various regions across Germany.”, stated Dr. Peter Fruhstorfer, CEO of Noselab GmbH.

Focus on Innovative, Non-Invasive Brain Diagnostics

The program covered scientific and clinical advances related to BNI-based biomarker discovery, diagnostic workflows, and future clinical applications. These topics align closely with Noselab’s mission to establish non-invasive, nasal-secretion–based diagnostic tools that provide a safe and accessible Window to the Brain.

These sessions reflected Noselab’s core vision: Revolutionizing the understanding, diagnosis and treatment of brain disorders leveraging the brain-nose interface — a main pillar of Noselab’s diagnostic platform. This transformational vision was also on display recently at BIO-Europe 2025 in Vienna, where Noselab showcased its diagnostic approach to a global biotech audience.

Building Momentum and Community

The strong interdisciplinary and international participation underscored the growing importance of the BNI field and Noselab´s leadership position. The symposium not only deepened the scientific conversation but also confirmed the need and laid the groundwork for new collaborations, academic partnerships, and translational projects. With many new relationships formed, the company is confident that this community will accelerate both fundamental understanding and clinical development of BNI-based technologies.

Looking Ahead

Following the success of this inaugural symposium, Noselab plans to establish the Brain-Nose Symposium as a recurring event and will initiate follow-up activities for further interdisciplinary dialogue and future collaborations.

“At Noselab we believe that the Brain-Nose Symposium can become a central forum for driving innovation, shaping the future of the BNI field, and for opening new avenues for diagnosis and therapy. So, stay tuned as we´re looking forward to welcome you at our next Symposium in 2026!”, Fruhstorfer concluded.

Learn more about Noselab GmbH or let´s get in touch.

Noselab GmbH is a leading innovator in diagnostic breakthrough technology, specializing in the early detection and management of neurodegenerative diseases. Leveraging its revolutionary diagnostic platform, which analyzes brain relevant biomarkers in nasal secretion collected from the vicinity of the brain-nose-interface, Noselab aims to transform disease understanding, disease diagnosis, personalized patient profiling and enable monitoring of brain biology over time to improve patient outcomes. As a member of the Munich Bio-M cluster, Noselab collaborates with leading experts and institutions to drive innovation and foster collaboration in biomedical research and development.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with the development of diagnostic technologies, the success of clinical trials, the regulatory approval process, market acceptance of products, competition, intellectual property rights, and other risks inherent in the diagnostic development industry.

Additionally, any statements regarding future performance, achievements, or financial outlook of the Company are forward-looking statements and are subject to risks and uncertainties. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement.